share_log

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga ·  00:31

Gainers

  • Tharimmune (NASDAQ:THAR) stock moved upwards by 106.1% to $4.18 during Wednesday's regular session. The market value of their outstanding shares is at $4.8 million.
  • Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 51.76% to $0.63. The company's market cap stands at $9.3 million.
  • Xilio Therapeutics (NASDAQ:XLO) stock rose 35.29% to $1.34. The company's market cap stands at $58.8 million.
  • Omnicell (NASDAQ:OMCL) stock rose 33.25% to $53.46. The company's market cap stands at $2.4 billion. The company's, Q3 earnings came out today.
  • CVRx (NASDAQ:CVRX) stock increased by 32.83% to $14.27. The company's market cap stands at $309.7 million. As per the press release, Q3 earnings came out yesterday.
  • CalciMedica (NASDAQ:CALC) shares rose 31.66% to $5.17. The company's market cap stands at $55.6 million.

Losers

  • Applied DNA Sciences (NASDAQ:APDN) stock decreased by 37.0% to $0.2 during Wednesday's regular session. The company's market cap stands at $2.0 million.
  • AnaptysBio (NASDAQ:ANAB) stock declined by 25.56% to $22.93. The company's market cap stands at $692.4 million.
  • Sage Therapeutics (NASDAQ:SAGE) shares declined by 20.46% to $6.75. The market value of their outstanding shares is at $411.7 million. As per the news, the Q3 earnings report came out yesterday.
  • Option Care Health (NASDAQ:OPCH) shares decreased by 20.14% to $24.36. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today.
  • Cormedix (NASDAQ:CRMD) shares declined by 15.32% to $10.98. The market value of their outstanding shares is at $613.5 million. As per the news, the Q3 earnings report came out today.
  • Hims & Hers Health (NYSE:HIMS) shares decreased by 15.06% to $18.89. The company's market cap stands at $4.0 billion.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment